Reanalyzing the Economic Burden of Antimicrobial Resistance: Socioeconomic Inequality and Local Policy Recommendations in U.S. Low-and Middle-Income Regions
Antimicrobial resistance (AMR) is one of the greatest global and public health crises of the modern age. AMR has contributed to increased healthcare costs, prolonged hospitalization, reduced productivity, and rising mortality rates worldwide. While AMR is commonly viewed as a global threat, existing studies fail to account for socioeconomic disparities present in low- and middle-income countries (LMICs) and low- and middle-income regions (LMIRs) within high-income countries such as the United States. This study investigates how socioeconomic vulnerabilities in LMIRs in the United States affect contributors to AMR’s economic burden and identifies policy interventions that could improve domestic AMR containment strategies. Because direct healthcare expenditures were not measured, this study utilized surveillance capacity, AMR-related outbreak rates, antibiotic prescription patterns, diagnostic capacity, and supply shortages as established proxies for factors that influence the economic burden of AMR. This study utilized a mixed-methods research design combining targeted survey data from physicians, health economists, and healthcare administrations with secondary data analysis from public health databases. The results show that higher socioeconomic vulnerability was associated with lower diagnostic and infrastructural capacity and increased supply shortages. These disparities support the implementation of local policy changes, including expanded rapid diagnostic technologies, improved antimicrobial stewardship programs, standardized surveillance systems, increased healthcare funding, and broader educational initiatives.
References
[1]
Agency for Toxic Substances and Disease Registry (ATSDR) (2022). Overall SVI Nationwide Comparison. Place and Health—Geospatial Research, Analysis, and Services Program (GRASP). https://www.atsdr.cdc.gov/place-health/php/svi/svi-interactive-map.html
[2]
Agency for Toxic Substances and Disease Registry (ATSDR) (2024). Social Vulnerability Index. Place and Health—Geospatial Research, Analysis, and Services Program (GRASP). https://www.atsdr.cdc.gov/place-health/php/svi/index.html
[3]
Ahmed, S. K., Hussein, S., Qurbani, K., Ibrahim, R. H., Fareeq, A., Mahmood, K. A. et al. (2024). Antimicrobial Resistance: Impacts, Challenges, and Future Prospects. Journal of Medicine, Surgery, and Public Health, 2, Article ID: 100081. https://doi.org/10.1016/j.glmedi.2024.100081
[4]
Altman, D. G., & Royston, P. (2006). The Cost of Dichotomising Continuous Variables. BMJ, 332, Article No. 1080. https://doi.org/10.1136/bmj.332.7549.1080
Butler, D. C., Petterson, S., Phillips, R. L., & Bazemore, A. W. (2013). Measures of Social Deprivation That Predict Health Care Access and Need within a Rational Area of Primary Care Service Delivery. Health Services Research, 48, 539-559. https://doi.org/10.1111/j.1475-6773.2012.01449.x
[7]
Centers for Disease Control and Prevention (2019). Antibiotic Resistance Threats in the United States. U.S. Department of Health and Human Services, CDC.
[8]
Centers for Disease Control and Prevention (2024a). Inpatient Antibiotic Use. Antimicrobial Resistance & Patient Safety Portal. https://arpsp.cdc.gov/profile/inpatient-antibiotic-use/all
[9]
Centers for Disease Control and Prevention (2024b). Hospital Antibiotic Stewardship by State. Antimicrobial Resistance & Patient Safety Portal. https://arpsp.cdc.gov/profile/stewardship
[10]
Centers for Disease Control and Prevention (2024c). Long-Term Hospital Antibiotic Stewardship by State. Antimicrobial Resistance & Patient Safety Portal. https://arpsp.cdc.gov/profile/ltc/united-states-United%20States
[11]
Centers for Disease Control and Prevention (2024d). HAI Progress Reports. National Healthcare Safety Network (NHSN). https://www.cdc.gov/nhsn/datastat/progress-report.html#anchor_18655
[12]
Centers for Disease Control and Prevention (2024e). Antibiotic Prescriptions per 1,000 Persons by State (Sextiles) for All Ages. Outpatient Antibiotics Prescriptions. https://www.cdc.gov/antibiotic-use/media/pdfs/2024-Annual-Report-508.pdf
[13]
Centers for Disease Control and Prevention (2026). 2024 National Healthcare Safety Network Antimicrobial Use Option Report. https://www.cdc.gov/nhsn/pdfs/datastat/2024-AU-Report-508.pdf
[14]
Dadgostar, P. (2019). Antimicrobial Resistance: Implications and Costs. Infection and Drug Resistance, 12, 3903-3910. https://doi.org/10.2147/idr.s234610
[15]
Founou, R. C., Founou, L. L., & Essack, S. Y. (2017). Clinical and Economic Impact of Antibiotic Resistance in Developing Countries: A Systematic Review and Meta-Analysis. PLOS ONE, 12, e0189621. https://doi.org/10.1371/journal.pone.0189621
[16]
Gandra, S., Alvarez-Uria, G., Turner, P., Joshi, J., Limmathurotsakul, D., & van Doorn, H. R. (2020). Antimicrobial Resistance Surveillance in Low-and Middle-Income Countries: Progress and Challenges in Eight South Asian and Southeast Asian Countries. Clinical Microbiology Reviews, 33. https://doi.org/10.1128/cmr.00048-19
[17]
Gandra, S., Barter, D. M., & Laxminarayan, R. (2014). Economic Burden of Antibiotic Resistance: How Much Do We Really Know? Clinical Microbiology and Infection, 20, 973-980. https://doi.org/10.1111/1469-0691.12798
[18]
Global Data Lab (2023). Subnational HDI. https://geohub.data.undp.org/data/bb81caa483a0856029f980d2d7e89177
[19]
KFF (2024). Health Insurance Coverage of the Total Population. https://www.kff.org/state-health-policy-data/state-indicator/total-population/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Employer%22,%22sort%22:%22desc%22%7D
[20]
Kind, A. J. H., & Buckingham, W. R. (2018). Making Neighborhood-Disadvantage Metrics Accessible—The Neighborhood Atlas. New England Journal of Medicine, 378, 2456-2458. https://doi.org/10.1056/nejmp1802313
[21]
Masoambeta, E., Mkwanda, C., Ibrahim, E., Chizani, K., Chapuma, C., Dzanja, P. et al. (2025). Economic Costing Methodologies for Drug-Resistant Bacterial Infections in Humans in Low-and Middle-Income Countries: A Systematic Review. Health Economics Review, 15, Article No. 47. https://doi.org/10.1186/s13561-025-00644-5
[22]
McGowan, J. E. (2001). Economic Impact of Antimicrobial Resistance. Emerging Infectious Diseases, 7, 286-292. https://doi.org/10.3201/eid0702.010228
[23]
Mestrovic, T., Aguilar, G. R., Swetschinski, L. R., Ikuta, K. S., Gray, A. P., Davis Weaver, N. et al. (2022). The Burden of Bacterial Antimicrobial Resistance in the WHO European Region in 2019: A Cross-Country Systematic Analysis. The Lancet Public Health, 7, e897-e913. https://doi.org/10.1016/s2468-2667(22)00225-0
[24]
O’Neill, J. (2016). Tackling Drug-Resistant Infections Globally: Final Report and Recommendations. The Review on Antimicrobial Resistance. https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf
[25]
OECD (2018). Stemming the Superbug Tide: Just a Few Dollars More. OECD Health Policy Studies. https://www.oecd.org/content/dam/oecd/en/publications/reports/2018/11/stemming-the-superbug-tide_g1g98de5/9789264307599-en.pdf
[26]
Oliveira, M., Antunes, W., Mota, S., Madureira-Carvalho, á., Dinis-Oliveira, R. J., & Dias da Silva, D. (2024). An Overview of the Recent Advances in Antimicrobial Resistance. Microorganisms, 12, Article No. 1920. https://doi.org/10.3390/microorganisms12091920
[27]
Poudel, A. N., Zhu, S., Cooper, N., Little, P., Tarrant, C., Hickman, M. et al. (2023). The Economic Burden of Antibiotic Resistance: A Systematic Review and Meta-Analysis. PLOS ONE, 18, e0285170. https://doi.org/10.1371/journal.pone.0285170
[28]
Robert Graham Center (2019). Social Deprivation Index (SDI). https://www.graham-center.org/maps-data-tools/social-deprivation-index.html
[29]
Shrestha, P., Cooper, B. S., Coast, J., Oppong, R., Do Thi Thuy, N., Phodha, T. et al. (2018). Enumerating the Economic Cost of Antimicrobial Resistance per Antibiotic Consumed to Inform the Evaluation of Interventions Affecting Their Use. Antimicrobial Resistance & Infection Control, 7, Article No. 98. https://doi.org/10.1186/s13756-018-0384-3
[30]
Sosa, A. D. J., Byarugaba, D. K., Amábile-Cuevas, C. F., Hsueh, P. R., Kariuki, S., & Okeke, I. N. (2010). Antimicrobial Resistance in Developing Countries (pp. 3-7). Springer. https://link.springer.com/book/10.1007/978-0-387-89370-9
[31]
Tesema, M. Y., & Birhanu, A. G. (2024). One Health Initiative to Mitigate the Challenge of Antimicrobial Resistance in the Perspectives of Developing Countries. Bulletin of the National Research Centre, 48, Article No. 19. https://doi.org/10.1186/s42269-024-01176-4
[32]
Thorpe, K. E., Joski, P., & Johnston, K. J. (2018). Antibiotic-Resistant Infection Treatment Costs Have Doubled since 2002, Now Exceeding $2 Billion Annually. Health Affairs, 37, 662-669. https://doi.org/10.1377/hlthaff.2017.1153
[33]
United States Census Bureau (2019). State MDI Rates 2010 to 2019. Multidimensional Deprivation Index (MDI). https://www.census.gov/topics/income-poverty/poverty/about/related-sites/rates.html
[34]
United States Census Bureau (2026). State Population Totals and Components of Change: 2020-2025. https://www.census.gov/data/tables/time-series/demo/popest/2020s-state-total.html
[35]
World Bank Group (2017). Drug-Resistant Infections: A Threat to Our Economic Future. World Bank Group. https://openknowledge.worldbank.org/server/api/core/bitstreams/35f0bc69-a13b-5062-928d-f62f223f4b22/content
[36]
World Health Organization (2015). Global Action Plan on Antimicrobial Resistance. https://www.who.int/publications/i/item/9789241509763
[37]
World Health Organization WHO (2014). Antimicrobial Resistance: Global Report on Surveillance. World Health Organization. https://www.who.int/publications/i/item/9789241564748